A study to assess the safety and biological effects of adding interferon-alpha-n3 to a strategic therapeutic intervention protocol in African patients with HIV

Trial Profile

A study to assess the safety and biological effects of adding interferon-alpha-n3 to a strategic therapeutic intervention protocol in African patients with HIV

Planning
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs Interferon alpha-n3 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Bioclones; Hemispherx Biopharma
  • Most Recent Events

    • 25 Aug 2014 New trial record
    • 14 Jul 2014 Hemispherx Biopharma and Bioclones announce that they are seeking approval to conduct trials using Alferon according to a Hemispherex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top